Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
megestrol acetate nano-suspension (DW5221)
- Development stage
- Unknown
- Lead developer
- Daewon Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DW5221 is a nano-suspension formulation of megestrol acetate developed by Daewon Pharmaceutical. Megestrol acetate is a synthetic derivative of the hormone progesterone and acts as a progesterone receptor agonist. It is classified as an antiandrogen, antineoplastic agent, and small molecule within the pregnadiene class. The primary indications for this formulation are anorexia and cachexia. The drug is not considered a new molecular entity but represents an advanced formulation designed to improve bioavailability or patient outcomes in these conditions[1][9].
- Brand names
- DW-ES(B)
- Other names
- megestrol acetatemegestrol
02
Targets
AR (Adrenergic receptors)GR (Glucocorticoid receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on megestrol acetate nano-suspension (DW5221).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on megestrol acetate nano-suspension (DW5221).